| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -12,266 | -14,646 | -24,320 | NaN |
| Stock-based compensation expense | 689 | 1,692 | 882 | NaN |
| Depreciation and amortization | 252 | 5 | 16 | NaN |
| Non-cash lease expense | 71 | 69 | 199 | NaN |
| Loss on disposal of property and equipment | NaN | 0 | 0 | NaN |
| Change in fair value of warrant and conversion option liabilities | 91 | 4,017 | -517 | NaN |
| Prepaid expenses and other current assets | -2,054 | -841 | -1,606 | NaN |
| Other assets | -64 | 0 | 0 | NaN |
| Accounts payable | 1,700 | -443 | 91 | NaN |
| Accrued expenses and other current liabilities | -1,300 | 1,808 | -4,310 | NaN |
| Deferred revenue | NaN | 0 | 0 | NaN |
| Other liabilities | -87 | 201 | -518 | NaN |
| Net cash used in operating activities | -8,732 | -6,456 | -26,871 | NaN |
| Proceeds from exercise of pre-funded warrants | NaN | 40 | NaN | NaN |
| Purchases of property and equipment | 10 | NaN | NaN | NaN |
| Proceeds from exercise of common stock options | NaN | 5 | 0 | NaN |
| Proceeds from issuance of common stock and warrants | NaN | 50,000 | NaN | NaN |
| Net cash used in investing activities | -10 | NaN | NaN | NaN |
| Proceeds from issuance of common stock related to employee stock purchase plan | NaN | 22 | 3 | NaN |
| Proceeds from debt, gross | 14,146 | NaN | NaN | NaN |
| Repayment of debt | 0 | 841 | 1,216 | NaN |
| Payment of debt and equity offering costs | 220 | 3,701 | NaN | NaN |
| Tax withholding payments on restricted stock units | 10 | 831 | 0 | NaN |
| Net cash provided by (used in) financing activities | 13,916 | 44,694 | -1,213 | NaN |
| Restricted cash | NaN | NaN | NaN | 35 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 5,174 | 38,238 | -28,084 | NaN |
| Cash and cash equivalents, at carrying value, ending balance | NaN | NaN | NaN | 16,387 |
| Cash, cash equivalents, and restricted cash at beginning of period | 48,942 | 10,704 | 16,422 | NaN |
| Cash, cash equivalents, and restricted cash at end of period | 54,116 | 48,942 | 10,704 | 16,422 |
SPRUCE BIOSCIENCES, INC. (SPRB)
SPRUCE BIOSCIENCES, INC. (SPRB)